FDA 加速审批及其对合理的配方和健康计划设计的影响。
FDA expedited approval and implications for rational formulary and health plan design.
机构信息
Humana, Inc., Louisville, KY.
出版信息
J Manag Care Spec Pharm. 2021 May;27(5):682-684. doi: 10.18553/jmcp.2021.27.5.682.
Abstract
No funding supported this commentary. The authors are employed by Humana, Inc. Shrank reports board of directors work for GetWell Network and NCQA. The other authors have nothing to disclose.
摘要
本评论不接受任何资金支持。作者受雇于 Humana，Inc. Shrank 报告董事会为 GetWell Network 和 NCQA 工作。其他作者没有什么可披露的。
相似文献
1
FDA expedited approval and implications for rational formulary and health plan design.FDA 加速审批及其对合理的配方和健康计划设计的影响。
J Manag Care Spec Pharm. 2021 May;27(5):682-684. doi: 10.18553/jmcp.2021.27.5.682.
2
Biosimilar Products in the Modern U.S. Health Care and Regulatory Landscape.生物类似药产品在现代美国医疗保健和监管格局中的作用。
J Manag Care Spec Pharm. 2017 Dec;23(12):1255-1259. doi: 10.18553/jmcp.2017.23.12.1255.
3
Comparing patient access to pharmaceuticals in the UK and US.比较英国和美国患者获取药品的情况。
Appl Health Econ Health Policy. 2006;5(3):177-87. doi: 10.2165/00148365-200605030-00004.
4
Pharmaceuticals issue brief: managed care drug formularies: year end report-2003.药品问题简报：管理式医疗药品处方集：2003年年终报告
Issue Brief Health Policy Track Serv. 2003 Dec 31:1-8.
5
Few new drugs deserve expedited regulatory treatment.很少有新药值得加快监管审批。
J Manag Care Spec Pharm. 2021 May;27(5):685-688. doi: 10.18553/jmcp.2021.27.5.685.
6
Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.三层药品目录对儿童注意力缺陷多动障碍药物治疗的影响。
Arch Gen Psychiatry. 2005 Apr;62(4):435-41. doi: 10.1001/archpsyc.62.4.435.
7
Mathematical models for formulary committees.处方委员会的数学模型。
Value Health. 2001 Sep-Oct;4(5):347. doi: 10.1046/j.1524-4733.2001.45001.x.
8
Changes of ticagrelor formulary tiers in the USA: targeting private insurance providers away from government-funded plans.替格瑞洛在美国医保目录层级的变化：目标是针对私人保险提供商而非政府资助计划。
Cardiology. 2013;126(3):187-90. doi: 10.1159/000353810. Epub 2013 Sep 12.
9
Prescription drug formulary design, preferred-product marketshare, and formulary noncompliance: a study of proton-pump inhibitors.处方药处方集设计、首选产品市场份额与处方集不依从性：质子泵抑制剂研究
Manag Care Interface. 2005 Aug;18(8):39-45.
10
Formulary decisions for pre-1938 medications.1938年以前药物的处方集决策。
Am J Health Syst Pharm. 2008 Jul 15;65(14):1363-7. doi: 10.2146/ajhp070601.
引用本文的文献
1
Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness.加拿大肿瘤药物的有条件药物批准上市途径：评估资格和监管响应性的挑战与建议
Front Med (Lausanne). 2022 Feb 3;8:818647. doi: 10.3389/fmed.2021.818647. eCollection 2021.
本文引用的文献
1
Gene therapy: evidence, value and affordability in the US health care system.基因治疗：美国医疗体系中的证据、价值和可负担性。
J Comp Eff Res. 2018 Jan;7(1):15-28. doi: 10.2217/cer-2017-0068. Epub 2017 Nov 16.
Zotero 插件